NEW YORK, Jan 19 (Reuters) - Mylan NV has yet to
reach a settlement with the U.S. Department of Justice over the
classification in the Medicaid program of its life-saving EpiPen
allergy treatment, according to a letter from a regulatory
agency disclosed on Thursday.
Read more
No comments:
Post a Comment